Product logins

Find logins to all Clarivate products below.


Methicillin-Resistant Staphylococcus Aureus Infections – Epidemiology – Mature Markets Data

Clarivate Epidemiology’s coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of MRSA for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s MRSA forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of MRSA events per year?
  • Of all people diagnosed with MRSA, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MRSA over the forecast period?

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to Microsoft Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology provides at least 10 years of forecast data for the following MRSA patient populations:

  • Diagnosed MRSA events by treatment.
  • Diagnosed MRSA events.
  • Diagnosed MRSA events by bloodstream infection (BSI).
  • Diagnosed MRSA events by complicated intra-abdominal infection (cIAI).
  • Diagnosed MRSA events by skin and skin structure infection (SSSI).
  • Diagnosed MRSA events by hospital-acquired pneumonia (HAP).
  • Diagnosed MRSA events by healthcare-acquired pneumonia (HCAP).
  • Diagnosed MRSA events by nosocomial pneumonia (NP).
  • Diagnosed MRSA events by surgical site infection (SSI).
  • Diagnosed MRSA events by SSSI and complicated skin and skin structure infection (cSSSI).
  • … and more (details available on request).

Note: Coverage may vary by country and region.

Related Market Assessment Reports

Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Report
Ulcerative Colitis – Geographic Focus: China – Ulcerative Colitis – China In-Depth (China)
Ulcerative colitis (UC) is a chronic, progressive inflammatory bowel disease marked by inflammation and ulceration of the colon and rectum. The primary objective of UC pharmacotherapy is to induce…